UY27301A1 - USE AND COMPOSITIONS OF ANTIPROGESTINES FOR THE TREATMENT OF PROSTATE DISEASES - Google Patents

USE AND COMPOSITIONS OF ANTIPROGESTINES FOR THE TREATMENT OF PROSTATE DISEASES

Info

Publication number
UY27301A1
UY27301A1 UY27301A UY27301A UY27301A1 UY 27301 A1 UY27301 A1 UY 27301A1 UY 27301 A UY27301 A UY 27301A UY 27301 A UY27301 A UY 27301A UY 27301 A1 UY27301 A1 UY 27301A1
Authority
UY
Uruguay
Prior art keywords
compositions
antiprogestines
treatment
prostate diseases
antiprogestin
Prior art date
Application number
UY27301A
Other languages
Spanish (es)
Inventor
Jens Hoffmann
Rosemarie Lichtner
Ulrike Fuhrmann
Gerhard Siemeister
Martin Schneider
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of UY27301A1 publication Critical patent/UY27301A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Métodos y usos para tratar enfermedades de próstata, en particular cáncer de próstata e hiperplasia benigna de la próstata, en mamíferos macho, con antiprogestinas, en particular, la antiprogestina 11beta - (4-acetilfenil) - 17beta-hidroxi- 17 alfa- (1,1,2,2,2-pentafluoroetil) -estra-4, 9-dien-3-ona, o un derivado o análogo de la misma aceptable para uso farmacéutico. La invención se relaciona además con composiciones farmacéuticas que comprenden dicha antiprogestina.Methods and uses to treat prostate diseases, in particular prostate cancer and benign prostatic hyperplasia, in male mammals, with antiprogestins, in particular, antiprogestin 11beta - (4-acetylphenyl) - 17 beta-hydroxy-17 alpha- (1 , 1,2,2,2-pentafluoroethyl) -estra-4, 9-diene-3-one, or a derivative or analog thereof acceptable for pharmaceutical use. The invention further relates to pharmaceutical compositions comprising said antiprogestin.

UY27301A 2001-05-25 2002-05-21 USE AND COMPOSITIONS OF ANTIPROGESTINES FOR THE TREATMENT OF PROSTATE DISEASES UY27301A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01250185 2001-05-25

Publications (1)

Publication Number Publication Date
UY27301A1 true UY27301A1 (en) 2003-02-28

Family

ID=8181589

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27301A UY27301A1 (en) 2001-05-25 2002-05-21 USE AND COMPOSITIONS OF ANTIPROGESTINES FOR THE TREATMENT OF PROSTATE DISEASES

Country Status (6)

Country Link
EP (1) EP1392399A1 (en)
JP (2) JP2004531561A (en)
AR (1) AR034046A1 (en)
PE (1) PE20021138A1 (en)
UY (1) UY27301A1 (en)
WO (1) WO2002094379A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3733478A1 (en) * 1987-10-01 1989-04-13 Schering Ag ANTIGESTAGEN AND ANTIOOTROGENIC COMPOUNDS FOR THE INTRODUCTION OF BIRTH AND PREGNANCY, AND THE TREATMENT OF GYNAECOLOGICAL DISORDER AND HORMONE-RELATED TUMORS
DE4039561A1 (en) * 1990-12-07 1992-07-09 Schering Ag USE OF ANTIGESTAGENS FOR THE MANUFACTURE OF MEDICAMENTS
DE4318371A1 (en) * 1993-05-28 1994-12-01 Schering Ag Agent containing a compound with antiandrogenic and a compound with competitive, progesterone-antagonistic effect
DE19706061A1 (en) * 1997-02-07 1998-08-13 Schering Ag Anti-gestagen effective steroids with fluorinated 17alpha alkyl chain
DK1326617T3 (en) * 2000-10-18 2006-12-18 Schering Ag Use of 11beta (acetylphenyl) -17beta-hydroxy-17alpha (1,1,2,2-pentafluoroethyl) estra-4,9-dien-3-one in the manufacture of a medicament for the treatment of breast cancer, ovarian cancer, endometrial cancer , myeloma and meningitis
SK287124B6 (en) * 2000-10-18 2009-12-07 Schering Aktiengesellschaft Use of an antiprogestin for preparing a medicament

Also Published As

Publication number Publication date
EP1392399A1 (en) 2004-03-03
AR034046A1 (en) 2004-01-21
PE20021138A1 (en) 2003-01-11
WO2002094379A1 (en) 2002-11-28
JP2004531561A (en) 2004-10-14
JP2010077157A (en) 2010-04-08

Similar Documents

Publication Publication Date Title
HUP0100586A2 (en) Pharmaceutical compositions treating lower urinary tract symptoms
NZ285159A (en) Treatment of benign prostatic hyperplasia, endometriosis, prostatic carcinoma and obesity by administration of droloxifene
CY1104981T1 (en) USE OF ANTI-PROGESTONES FOR THE PREVENTION AND TREATMENT OF HORMONE DEPENDENT DISEASES
ATE556706T1 (en) FAT ALCOHOL-DRUG CONJUGATES
AR028296A1 (en) SYNERGISTIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
TR200101481T2 (en) Cancer treatment composition and method using natural herbal essential oils.
BRPI0207961B8 (en) use of epothilone and capecitabine analogues to manufacture medicine to treat solid cancerous tumors and kit comprising said compounds.
ES2133270T3 (en) COMBINATION THERAPY FOR PROPHYLAXIS AND / OR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA.
UY26929A1 (en) ANTIANGIOGEN POLIPEPTIDES AND METHODS TO INHIBIT THE ANGIOGENESIS
BR0111196A (en) Compositions and use thereof for treatment of flaviviruses and pestiviruses
GT199900147A (en) 1, 2, 3, 4- TETRAHIDROQUINOLINAS 2-SUBSTITUTED 4-AMINO SUBSTITUTED.
DK1112067T3 (en) Use of acetylcholinesterase inhibitors for the preparation of pharmaceutical compositions for the treatment of functional and / or organic pain syndromes
DE60105448D1 (en) SOLID DISPERSIONS WITH NITRATIVE ACTIVE INGREDIENTS
BR0318278A (en) aminocyclohexyl ether compounds and uses thereof
BR0111630A (en) Insect Spiral
AU4830097A (en) Use of an extract of Cimicifuga
BR0108728A (en) Pharmaceutical Combination Therapy, and, Method for Treating a Cancer.
ES2188995T3 (en) USE OF AN INHIBITOR OF THE H +, K + -ATPASA IN THE TREATMENT OF NASAL POLYPS.
EP1743656A3 (en) Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention
UY27301A1 (en) USE AND COMPOSITIONS OF ANTIPROGESTINES FOR THE TREATMENT OF PROSTATE DISEASES
EE200300157A (en) Use of antiprogestins to induce apoptosis in a cell
ATE258801T1 (en) MATRIX PROTEIN COMPOSITIONS TO INDUCE APOPTOSIS
HUP0302629A2 (en) Pharmaceutical compositions comprising a combination camptothecin and a stilbene derivative for the treatment of cancer
ECSP034605A (en) USE OF ANTIPROGESTINES FOR PROFILAXIS AND TREATMENT OF HORMONE DEPENDENT DISEASES
NO20001846L (en) New pharmaceutically active compounds, their preparation and use as ECE inhibitors

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20141217